Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-subject decoding of internal mental states using predictive time-series modeling.

Science bulletin·2026
Same author

Aberrant dynamic functional architecture in major depressive disorder: Vertex-Wise large-sample fMRI analyses reveal network-specific alterations and symptom associations.

Translational psychiatry·2026
Same author

Transfer learning from 2D natural images to 4D fMRI brain images via geometric mapping.

Medical image analysis·2026
Same author

The long-term clinical and functional outcomes of psychiatric patients with catatonia: A 5-year follow-up.

Asian journal of psychiatry·2026
Same author

Dynamic changes in hemispheric lateralization in major depressive disorder correlate with neurotransmitter and genetic profiles: a DIRECT consortium study.

Translational psychiatry·2025
Same author

Structural Connectome Architecture Shapes Cortical Atrophy in Major Depressive Disorder: A Chinese DIRECT Consortium Study.

Biological psychiatry·2025

Related Experiment Video

Updated: Jun 15, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.

Chuan-Yue Wang1, Yu-Tao Xiang, Zhuo-Ji Cai

  • 1Beijing Anding Hospital, Capital Medical University, China. wang_cy@ccmu.edu.cn <wang_cy@ccmu.edu.cn>

The American Journal of Psychiatry
|March 17, 2010
PubMed
Summary

Maintaining the full therapeutic dose of risperidone for schizophrenia patients significantly reduces relapse rates compared to dose reductions. Full-dose treatment also led to greater improvement in psychotic symptoms with no increase in side effects.

Related Experiment Videos

Last Updated: Jun 15, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Area of Science:

  • Psychiatry
  • Clinical Pharmacology
  • Neuroscience

Background:

  • Schizophrenia relapse prevention is critical in maintenance treatment.
  • Optimal dosing strategies for long-term schizophrenia management require further investigation.

Purpose of the Study:

  • To compare the efficacy of maintaining the initial therapeutic dose versus reducing the dose in schizophrenia maintenance treatment.
  • To determine the optimal duration of full-dose treatment to prevent relapse.

Main Methods:

  • A multicenter, open-label, randomized controlled trial involving 404 clinically stabilized schizophrenia patients.
  • Patients were assigned to three groups: no dose reduction, 4-week dose reduction, or 26-week dose reduction.
  • The study followed patients for a 1-year period post-randomization.

Main Results:

  • The no-dose-reduction group had a significantly lower relapse rate (9.4%) compared to the 4-week (30.5%) and 26-week (19.5%) groups.
  • Mean time to relapse was longest in the no-dose-reduction group (683 days).
  • Patients on the full dose showed greater reduction in psychotic symptom severity.

Conclusions:

  • Continuing the full therapeutic dose of risperidone during maintenance is more effective in preventing relapse than dose reduction.
  • Dose reduction after 4 or 26 weeks increases relapse risk in schizophrenia.
  • No significant differences in side effects were observed across the treatment groups.